Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 1/2018

Open Access 01-01-2018 | Clinical Guides in Oncology

SEOM clinical guideline for treatment of cancer pain (2017)

Authors: C. Jara, S. del Barco, C. Grávalos, S. Hoyos, B. Hernández, M. Muñoz, T. Quintanar, J. A. Meana, C. Rodriguez, R. de las Peñas

Published in: Clinical and Translational Oncology | Issue 1/2018

Login to get access

Abstract

Pain is a highly prevalent symptom in patients with cancer. Despite therapeutic advances and well-accepted treatment guidelines, a percentage of patients with pain are under-treated. Currently, it has been recognized that several barriers in pain management still exist and, in addition, there are new challenges surrounding complex subtypes of pain, such as breakthrough and neuropathic pain, requiring further reviews and recommendations. This is an update of the guide our society previously published and represents the continued commitment of SEOM to move forward and improve supportive care of cancer patients.
Literature
1.
Escobar Álvarez Y, Rodríguez Sánchez CA, Caballero Martínez F, Recuero Cuervo V, Camps HC. Professional survey on knowledge and clinical patterns of pain management in Spanish medical oncology. Clin Transl Oncol. 2010;12:819–24.CrossRefPubMed
2.
van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manag. 2016;51(6):1070–90.CrossRef
3.
Porta-Sales J, Nabal-Vicuna M, Vallano A, Espinosa J, Planas-Domingo J, Verger-Fransoy E, et al. Have we improved pain control in cancer patients. A multicenter study of ambulatory and hospitalized cancer patients. J Palliat Med. 2015;18(11):923–32.CrossRefPubMed
4.
Pérez C, Sánchez-Martínez N, Ballesteros A, Blanco T, Collazo A, González F, et al. Prevalence of pain and relative diagnostic performance of screening tools for neuropathic pain in cancer patients: a cross sectorial study. Eur J Pain. 2015;19(6):752–61.CrossRefPubMed
5.
Gómez-Batiste X, Madrid F, Moreno F, Gracia A, Trelis J, Nabal M, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manag. 2002;24(1):45–52.CrossRef
6.
Dómine M, Díaz Fernández N, Sánchez C, de Ibargüen B, Zugazabeitia Olabarría L, Martínez Lozano J, Poza de Celis R, et al. Association of performance status and pain in metastatic bone pain management in the Spanish clinical setting. Adv Ther. 2017;34(1):136–47.CrossRef
7.
Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420–33.CrossRefPubMed
8.
Pargeon KL, Hailey BJ. Barriers to effective cancer pain management: a review of the literature. J Pain Symptom Manag. 1999;18(5):358–68.CrossRef
9.
Allard P, Maunsell E, Labbe J, Dorval M. Educational interventions to improve cancer pain control: a systematic review. J Palliat Med. 2001;4(2):191–203.CrossRefPubMed
10.
11.
12.
Cancer-Related Pain Management. Toronto (ON): Cancer Care Ontario; 2012 Apr 3 [Education and Information 2011 Sep]. Program in Evidence-based Care Evidence-based Series No.: 16-2 Education and Information 2011. Retrieved from http://​www.​cancercare.​on.​ca/​.
13.
14.
Derry S, Wiffen PJ, Moore RA, McNicol ED, Bell RF, Carr DB, McIntyre M, Wee B. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database Syst Rev. 2017;7:CD012638.PubMed
15.
Stocker M, Vardy J, Pillai A, Warr D. Acetaminophen (paracetamol) improves pain and wellbeing in people with advanced cancer already receiving a Sorong opioid regimen: a randomized, doubled-blind, placebo-controlled cross-over trial. J Clin Oncol. 2004;22(16):3389–94.CrossRef
16.
Ripamonti CI, Bandieri E, Roila F, on behalf of the ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22(Suppl 6):vi69–77.PubMed
17.
Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, et al. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) – results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study. Eur J Pain. 2017;21(9):1485–94.CrossRefPubMedPubMedCentral
18.
19.
20.
NCCN Clinical Practice Guidelines in Oncology. Adult Cancer Pain.v. 2.2017. National Comprehensive Cancer Network. 2017.
21.
22.
23.
Escobar Y, Mondéjar R. Tratamiento del Dolor. En: Manual SEOM de Cuidados Continuos. 2º Edición. 2014.
24.
Paice J, Portenoy R, Lacchetti C, Campbell T, Cheville A, Citron M, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:3325–45.CrossRefPubMed
25.
Mercadante S. New drugs for pain management in advanced cancer patients. Rev Expert Opin Pharmacother. 2017;18(5):497–502.CrossRef
26.
Mercadante S. The use of opioids for treatment of cancer pain. Expert Opin Pharmacother. 2015;16(3):389–94.PubMed
27.
Bao YJ, Hou W, Kong XY, Yang L, Xia J, Hua BJ, et al. Hydromorphone for cancer pain. Cochrane Database Syst Rev. 2016;10:CD011108.PubMed
28.
Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58–68.CrossRefPubMed
29.
30.
31.
Nicholson AB, Watson GR, Derry S, Wiffen PJ. Methadone for cancer pain. Cochrane Database Syst Rev. 2017;2:CD003971.PubMed
32.
Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315(15):1624–45.CrossRefPubMed
33.
Mercadante S, Bruera E. Opioid switching in cancer pain: From the beginning to nowadays. Crit Rev Oncol Hematol. 2016;99:241–8.CrossRefPubMed
34.
Gonzalez-Barboteo J, Porta-Sales J, Trelis-Navarro J, Gomez-Batiste X. Manual de rotación de opioides en el paciente oncológico. 1ª edición 2010. ISBN: 978-84-9406632-3-7.
35.
Vardy J, Agar M. Nonopioid drugs in the treatment of cancer pain. J Clin Oncol. 2014;32(16):1677–90.CrossRefPubMed
36.
Jonkman K, van de Donk T, Dahan A. Ketamine for cancer pain: what is the evidence? Curr Opin Palliat Care. 2017;11(2):88–92.CrossRef
37.
38.
Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G, Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of the task group of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13(4):331–8.CrossRefPubMed
39.
40.
Hagen NA, Biondo P, Stiles C. Assessment and management of breakthrough pain in cancer patients: current approaches and emerging re- search. Curr Pain Headache Rep. 2008;12:241–8.CrossRefPubMed
41.
Virizuela JA, Escobar Y, Cassinello J, Borrega P, SEOM (Spanish Society of Clinical Oncology). Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice. Clin Transl Oncol. 2012;14(7):499–504.CrossRefPubMed
42.
Roberto A, Dandrea S, Greco MT, Corli O, Negri A, Pizzuto M, et al. Prevalence of neuropathic pain in cancer patients: pooled estimates from a systematic review of published literature and results from a survey conducted in 50 Italian Palliative Care Centers. J Pain Symptom Manag. 2016;51(6):1091–102.CrossRef
43.
Vadalouca A, Raptis E, Moka E, Zis P, Sykioti P, Siafaka I. Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. Pain Pract. 2012;12:219–51.CrossRefPubMed
44.
Grond S, Radbruch L, Meuser T, Sabatowski R, Loick G, Lehmann KA. Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain. 1999;79(1):15–20.CrossRefPubMed
45.
Langford RM, Knaggs R, Farquhar-Smith P, Dickenson AH. Is tapentadol different from classical opioids? A review of the evidence. Br J Pain. 2016;10(4):217–21.CrossRefPubMedPubMedCentral
46.
van den Beuken-van Everdingen MH, de Graeff A, Jongen JL, Dijkstra D, Mostovaya I, Vissers KC, et al. Pharmacological treatment of pain in cancer patients: the role of adjuvant analgesics, a systematic review. Pain Pract. 2017;17(3):409–19.CrossRefPubMed
47.
Yan PZ, Butler PM, Kurowski D, Perloff MD. Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain. Clin J Pain. 2014;30:613–29.PubMed
48.
Bennett MI, Laird B, van Litsenburg C, Nimour M. Pregabalin for the management of neuropathic pain in adults with cancer: a systematic review of the literature. Pain Med. 2013;14:1681–8.CrossRefPubMed
49.
Durad JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23(1):200–5.CrossRef
50.
Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359–67.CrossRefPubMedPubMedCentral
51.
Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59(4):850–6.CrossRefPubMed
52.
Simpson KH. Interventional techniques for pain management in palliative care. Medicine. 2011;39(11):645–7.CrossRef
53.
Raphael J, Hester J, Ahmedzai S, Barrie J, Farqhuar-Smith P, Williams J, et al. Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med. 2010;11(6):872–96.CrossRefPubMed
54.
Wyse JM, Chen YI, Sahai AV. Celiac plexus neurolysis in the management of unresectable pancreatic cancer: when and how? World J Gastroenterol. 2014;20(9):2186–92.CrossRefPubMedPubMedCentral
55.
Yan BM, Myers RP. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer. Am J Gastroenterol. 2007;102:430–8.CrossRefPubMed
56.
Cherny NJ, Chang V, Frager G, Ingham JM, Tiseo PJ, Popp B, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995;76:1283–93.CrossRefPubMed
57.
Buggay D, Jaffe KJ. Metastatic bone tumors of the pelvis and lower extremity. Surg Orthop Adv. 2003;12(4):192–9.
58.
McDonald R, Ding K, Brundage M, Meyer RM, Nabid A, Chabot P, et al. Effect of radiotherapy on painful bone metastases: a secondary analysis of the NCIC clinical trials group symptom control trial SC. 23. JAMA Oncol. 2017;3(7):953–9.CrossRefPubMed
59.
Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, et al. Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7(1):4.CrossRefPubMed
60.
Huisman M, van den Bosch MA, Wijlemans JW, van Vulpen M, van der Linden YM, Verkooijen HM. Effectiveness of reirradiation for painful bone metastases: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2012;84(1):8–14.CrossRefPubMed
61.
Kurup AN, Morris JM, Schmit GD, Atwell TD, Weisbrod AJ, Murthy NS, et al. Neuroanatomic considerations in percutaneous tumor ablation. Radiographics. 2013;33(4):1195–215.CrossRefPubMed
62.
63.
Balanescu AR, Feist E, Wolfram G, Davignon I, Smith MD, Brown MT, et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a doubleblind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis. 2014;73:1665–72.CrossRefPubMed
64.
Sopata M, Katz N, Carey W, Smith MD, Keller D, Verburg KM, Brown MT, et al. Efficacy and safety of tanezumab in the treatment of pain from bone metastases. Pain. 2015;156(9):1703–13.CrossRefPubMed
65.
Syrjala KL, Jensen MP, Mendoza ME, Yi JC, Fisher HM, Keefe FJ. Psychological and behavioral approaches to cancer pain management. J Clin Oncol. 2014;32:1703–11.CrossRefPubMedPubMedCentral
66.
Sheinfeld Gorin S, Krebs P, Badr H, Janke EA, Jim H, Spring B, et al. Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. J Clin Oncol. 2012;30(5):539–47.CrossRefPubMed
67.
68.
van den Beuken-van EM. Chronic pain in cancer survivors: a growing issue. J Pain Palliat Care Pharmacother. 2012;26:385–7.CrossRef
Metadata
Title
SEOM clinical guideline for treatment of cancer pain (2017)
Authors
C. Jara
S. del Barco
C. Grávalos
S. Hoyos
B. Hernández
M. Muñoz
T. Quintanar
J. A. Meana
C. Rodriguez
R. de las Peñas
Publication date
01-01-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 1/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1791-2

Other articles of this Issue 1/2018

Clinical and Translational Oncology 1/2018 Go to the issue

Correction

Correction to: SEOM clinical guideline of diagnosis and management of low-grade glioma (2017)

Clinical Guides in Oncology

SEOM clinical guidelines for anaplastic gliomas (2017)

Clinical Guides in Oncology

SEOM clinical guidelines for endometrial cancer (2017)

Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

Editorial

2017 SEOM guidelines: a multidisciplinary approach

Clinical Guides in Oncology

SEOM clinical guideline for treatment of kidney cancer (2017)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits